Absent FDA Guidance on Sequencing-Based Tests, Personalized Rx Experts Weigh in with Ideas

As personalized medicine stakeholders in industry and academia set their sights on sequencing-based platforms, the absence of regulation poses challenges but inspires creative suggestions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.